First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 129, Issue 3, Pages 829-838
Publisher
Springer Nature
Online
2011-07-30
DOI
10.1007/s10549-011-1685-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
- (2011) Nicholas J. Robert et al. Clinical Breast Cancer
- Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
- (2011) A. M. Jubb et al. CLINICAL CANCER RESEARCH
- Treatment-Related Mortality With Bevacizumab in Cancer Patients
- (2011) Vishal Ranpura et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bevacizumab and Heart Failure Risk in Patients With Breast Cancer: A Thorn in the Side?
- (2011) Nitin Verma et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study
- (2011) Miguel Martin et al. LANCET ONCOLOGY
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
- (2010) Edith A. Perez et al. BREAST CANCER RESEARCH AND TREATMENT
- 489 Bevacizumab (BV) in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer (mBC): PFS subgroup results from two phase III studies
- (2010) J. Glaspy et al. EJC SUPPLEMENTS
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy
- (2009) P. H. O'Donnell et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
- (2009) Robert Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- Platinum-based chemotherapy in triple-negative breast cancer
- (2008) B. Sirohi et al. ANNALS OF ONCOLOGY
- Racial Disparity in Breast Cancer and Functional Germ Line Mutation in Galectin-3 (rs4644): A Pilot Study
- (2008) V. Balan et al. CANCER RESEARCH
- Bevacizumab in the first-line treatment of metastatic breast cancer
- (2008) David Cameron EJC SUPPLEMENTS
- Management of toxicity in patients receiving therapy with bevacizumab
- (2008) David Miles EJC SUPPLEMENTS
- Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy
- (2008) Ji Eun Uhm et al. INTERNATIONAL JOURNAL OF CANCER
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More